Is Data Adequate To Support Warfarin Dosing Test Coverage? Comments Vary
This article was originally published in The Gray Sheet
Executive Summary
Stakeholder opinions on whether Medicare should cover warfarin dosing tests vary based on the commenters' views on the adequacy of existing data
You may also be interested in...
CDC Works To Track Evidence Gaps On Pharmacogenetic Tests
CMS is looking for the best ways to assess pharmacogenetic test data so it can keep its coverage policies current as new developments are made in personalized medicine
CDC Works To Track Evidence Gaps On Pharmacogenetic Tests
CMS is looking for the best ways to assess pharmacogenetic test data so it can keep its coverage policies current as new developments are made in personalized medicine
Paying For Personalized Medicine: Medicare CED Approach Advised
If CMS proceeds with a national coverage determination on diagnostics for patient-specific drug therapy, it should consider a Coverage with Evidence Development approach, the Personalized Medicine Coalition suggests in Sept. 26 comments to the agency